2015 | Focus Session: Parkinson’s

Michelle Cortez, Reporter, Bloomberg Businessweek
Frank Bennett, PhD, Senior Vice President of Research, Isis Pharmaceuticals
Michael Schwarzschild, MD, PhD, Chair, Parkinson Study Group (PSG) Executive Committee, MassGeneral Institute for Neurodegenerative Disease; Professor of Neurology, Harvard Medical School
Clemens Scherzer, MD, Director, Neurogenomics Lab and Parkinson Personalized Medicine Program, Brigham and Women’s Hospital/Massachusetts General Hospital; Associate Professor of Neurology, Harvard Medical School
Todd Sherer, PhD, CEO, The Michael J. Fox Foundation for Parkinson’s Research

Parkinson’s: Finally Crossing the Therapeutic Threshold
Parkinson’s disease, the progressive, degenerative, neurological movement disorder that affects more than one million people in the United States, has no cure. Despite this, effective treatments are getting closer. Panel members describe the great progress being made with experimental therapies to prevent, slow, or halt disease progression.